Immunosuppressive networks in the tumour environment and their therapeutic relevance (original) (raw)

• Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991–998 (2002).
  Article CAS Google Scholar
• Smyth, M. J., Godfrey, D. I. & Trapani, J. A. A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunol. 2, 293–299 (2001). References 1 and 2 re-visit and refine the concept of tumour immune surveillance. The authors provide their own opinions and views on this subject.
  Article CAS Google Scholar
• Melief, C. J. et al. Strategies for immunotherapy of cancer. Adv. Immunol. 75, 235–282 (2000).
  Article CAS PubMed Google Scholar
• Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807–839 (2003).
  CAS PubMed Google Scholar
• Finn, O. J. Cancer vaccines: between the idea and the reality. Nature Rev. Immunol. 3, 630–641 (2003).
  Article CAS Google Scholar
• Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunol. 3, 999–1005 (2002).
  Article CAS Google Scholar
• Gilboa, E. The promise of cancer vaccines. Nature Rev. Cancer 4, 401–411 (2004).
  Article CAS Google Scholar
• Schuler, G., Schuler-Thurner, B. & Steinman, R. M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138–147 (2003).
  Article CAS PubMed Google Scholar
• Yee, C. & Greenberg, P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nature Rev. Cancer 2, 409–419 (2002).
  Article CAS Google Scholar
• O'Neill, D. W., Adams, S. & Bhardwaj, N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104, 2235–2246 (2004).
  Article CAS PubMed Google Scholar
• Knutson, K. L., Schiffman, K. & Disis, M. L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107, 477–484 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hwu, P. & Freedman, R. S. The immunotherapy of patients with ovarian cancer. J. Immunother. 25, 189–201 (2002).
  Article CAS PubMed Google Scholar
• Figdor, C. G., de Vries, I. J., Lesterhuis, W. J. & Melief, C. J. Dendritic cell immunotherapy: mapping the way. Nature Med. 10, 475–480 (2004).
  Article CAS PubMed Google Scholar
• Melief, C. J. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58, 143–175 (1992).
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676–1680 (1988).
  Article CAS PubMed Google Scholar
• Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850–854 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Pamer, E. & Cresswell, P. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16, 323–358 (1998).
  Article CAS PubMed Google Scholar
• Itano, A. A. & Jenkins, M. K. Antigen presentation to naive CD4 T cells in the lymph node. Nature Immunol. 4, 733–739 (2003).
  Article CAS Google Scholar
• Mueller, S. N., Jones, C. M., Smith, C. M., Heath, W. R. & Carbone, F. R. Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J. Exp. Med. 195, 651–656 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Kaech, S. M. & Ahmed, R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nature Immunol. 2, 415–422 (2001).
  Article CAS Google Scholar
• van Stipdonk, M. J., Lemmens, E. E. & Schoenberger, S. P. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nature Immunol. 2, 423–429 (2001).
  Article CAS Google Scholar
• Wong, P. & Pamer, E. G. CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol. 21, 29–70 (2003).
  Article CAS PubMed Google Scholar
• Degli-Esposti, M. A. & Smyth, M. J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nature Rev. Immunol. 5, 112–124 (2005).
  Article CAS Google Scholar
• Spiotto, M. T. et al. Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17, 737–747 (2002).
  Article CAS PubMed Google Scholar
• Ochsenbein, A. F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058–1064 (2001).
  Article CAS PubMed Google Scholar
• Ochsenbein, A. F. et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl Acad. Sci. USA 96, 2233–2238 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Palmowski, M., Salio, M., Dunbar, R. P. & Cerundolo, V. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol. Rev. 188, 155–163 (2002).
  Article CAS PubMed Google Scholar
• Romero, P. et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188, 1641–1650 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, P. et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nature Immunol. 5, 141–149 (2004). Demonstrates that efficient TAA-specific priming in the tumour microenvironment is possible.
  Article CAS Google Scholar
• Feuerer, M. et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nature Med. 9, 1151–1157 (2003).
  Article CAS PubMed Google Scholar
• Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
  Article CAS PubMed Google Scholar
• Lanzavecchia, A. & Sallusto, F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr. Opin. Immunol. 13, 291–298 (2001).
  Article CAS PubMed Google Scholar
• Colonna, M., Trinchieri, G. & Liu, Y. J. Plasmacytoid dendritic cells in immunity. Nature Immunol. 5, 1219–1226 (2004).
  Article CAS Google Scholar
• Cerundolo, V., Hermans, I. F. & Salio, M. Dendritic cells: a journey from laboratory to clinic. Nature Immunol. 5, 7–10 (2004).
  Article CAS Google Scholar
• Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1339–1346 (2001). The first functional study of human tumour-associated plasmacytoid DCs. This paper shows that tumour-derived CXCL12 attracts plasmacytoid DCs and that tumour plasmacytoid DCs induce IL-10+ suppressive T cells.
  Article CAS PubMed Google Scholar
• Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med. 9, 562–567 (2003).
  Article CAS PubMed Google Scholar
• Curiel, T. J. et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64, 5535–5538 (2004).
  Article CAS PubMed Google Scholar
• Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096–1103 (1996). The first study showing that VEGF inhibits DC differentiation from CD34+ progenitor cells.
  Article CAS PubMed Google Scholar
• Munn, D. H. & Mellor, A. L. IDO and tolerance to tumors. Trends Mol. Med. 10, 15–18 (2004).
  Article CAS PubMed Google Scholar
• Bell, D. et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190, 1417–1426 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Iwamoto, M. et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer 104, 92–97 (2003).
  Article CAS PubMed Google Scholar
• Troy, A., Davidson, P., Atkinson, C. & Hart, D. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J. Urol. 160, 214–219 (1998).
  Article CAS PubMed Google Scholar
• Troy, A. J., Summers, K. L., Davidson, P. J., Atkinson, C. H. & Hart, D. N. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4, 585–593 (1998).
  CAS PubMed Google Scholar
• Kryczek, I. et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65, 465–472 (2005).
  CAS PubMed Google Scholar
• Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
  CAS PubMed Google Scholar
• Menetrier-Caux, C. et al. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92, 4778–4791 (1998).
  Article CAS PubMed Google Scholar
• Kryczek, I., Grybos, M., Karabon, L., Klimczak, A. & Lange, A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. Br. J. Cancer 82, 621–628 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Freedman, R. S., Deavers, M., Liu, J. & Wang, E. Peritoneal inflammation — a microenvironment for Epithelial Ovarian Cancer (EOC). J. Transl. Med. 2, 23 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Pasare, C. & Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299, 1033–1036 (2003).
  Article CAS PubMed Google Scholar
• Shono, T., Tofilon, P. J., Bruner, J. M., Owolabi, O. & Lang, F. F. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61, 4375–4381 (2001).
  CAS PubMed Google Scholar
• Wolff, H. et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997–5001 (1998).
  CAS PubMed Google Scholar
• Joki, T. et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 60, 4926–4931 (2000).
  CAS PubMed Google Scholar
• Kalinski, P., Schuitemaker, J. H., Hilkens, C. M. & Kapsenberg, M. L. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161, 2804–2809 (1998).
  CAS PubMed Google Scholar
• Sombroek, C. C. et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168, 4333–4343 (2002).
  Article CAS PubMed Google Scholar
• Jozefowski, S., Bobek, M. & Marcinkiewicz, J. Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved. Int. Immunopharmacol. 3, 865–878 (2003).
  Article CAS PubMed Google Scholar
• Akasaki, Y. et al. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 173, 4352–4359 (2004).
  Article CAS PubMed Google Scholar
• Shurin, G. V. et al. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61, 363–369 (2001).
  CAS PubMed Google Scholar
• Peguet-Navarro, J. et al. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170, 3488–3494 (2003).
  Article CAS PubMed Google Scholar
• Labeur, M. S. et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162, 168–175 (1999).
  CAS PubMed Google Scholar
• Dhodapkar, M. V. et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104, 173–180 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Jonuleit, H., Schmitt, E., Schuler, G., Knop, J. & Enk, A. H. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213–1222 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233–238 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769–779 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Choi, I. H. et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171, 4650–4654 (2003).
  Article CAS PubMed Google Scholar
• Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942–949 (2004). Provides a direct functional and clinical link between regulatory T cells and human tumour immunopathogenesis.
  Article CAS PubMed Google Scholar
• Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nature Rev. Immunol. 4, 336–347 (2004).
  Article CAS Google Scholar
• Brown, J. A. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257–1266 (2003).
  Article CAS PubMed Google Scholar
• Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 8, 793–800 (2002).
  Article CAS PubMed Google Scholar
• Strome, S. E. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63, 6501–6505 (2003).
  CAS PubMed Google Scholar
• Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293–12297 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Iwai, Y., Terawaki, S. & Honjo, T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17, 133–144 (2005). Reference 36 and 68–71 report that B7-H1 or PD-1 in the tumour microenvironment attenuates tumour-specific immunity and that blocking B7-H1 improves tumour immunity in vivo.
  Article CAS PubMed Google Scholar
• Sica, G. L. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849–861 (2003).
  Article CAS PubMed Google Scholar
• Prasad, D. V., Richards, S., Mai, X. M. & Dong, C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18, 863–873 (2003).
  Article CAS PubMed Google Scholar
• Zang, X. et al. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl Acad. Sci. USA 100, 10388–10392 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Tamura, H. et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97, 1809–1816 (2001).
  Article CAS PubMed Google Scholar
• Subudhi, S. K. et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J. Clin. Invest. 113, 694–700 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Munn, D. H. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867–1870 (2002).
  Article CAS PubMed Google Scholar
• Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med. 9, 1269–1274 (2003). Reference 77 and 78 document the relevance of IDO-expressing dendritic cells or tumours in tumour immune responses.
  Article CAS PubMed Google Scholar
• Grohmann, U. et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature Immunol. 3, 1097–1101 (2002).
  Article CAS Google Scholar
• Salio, M. et al. Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol. 33, 1052–1062 (2003).
  Article CAS PubMed Google Scholar
• Hartmann, E. et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63, 6478–6487 (2003).
  CAS PubMed Google Scholar
• Moseman, E. A. et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. 173, 4433–4442 (2004).
  Article CAS PubMed Google Scholar
• Gilliet, M. & Liu, Y. J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195, 695–704 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Conejo-Garcia, J. R. et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nature Med. 10, 950–958 (2004).
  Article CAS PubMed Google Scholar
• Kusmartsev, S. A., Li, Y. & Chen, S. H. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165, 779–785 (2000).
  Article CAS PubMed Google Scholar
• Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168, 689–695 (2002).
  Article CAS PubMed Google Scholar
• Schmielau, J. & Finn, O. J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61, 4756–4760 (2001).
  CAS PubMed Google Scholar
• Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678–689 (2001).
  Article CAS PubMed Google Scholar
• Bronte, V., Serafini, P., Apolloni, E. & Zanovello, P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24, 431–446 (2001).
  Article CAS PubMed Google Scholar
• Saio, M., Radoja, S., Marino, M. & Frey, A. B. Tumor-infiltrating macrophages induce apoptosis in activated CD8+ T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol. 167, 5583–5593 (2001).
  Article CAS PubMed Google Scholar
• Rodriguez, P. C. et al. L-arginine consumption by macrophages modulates the expression of CD3 ζ chain in T lymphocytes. J. Immunol. 171, 1232–1239 (2003).
  Article CAS PubMed Google Scholar
• Rodriguez, P. C. et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839–5849 (2004).
  Article CAS PubMed Google Scholar
• Matzinger, P. The danger model: a renewed sense of self. Science 296, 301–305 (2002).
  CAS PubMed Google Scholar
• Fuchs, E. J. & Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol. 8, 271–280 (1996).
  Article CAS PubMed Google Scholar
• Vakkila, J. & Lotze, M. T. Inflammation and necrosis promote tumour growth. Nature Rev. Immunol. 4, 641–648 (2004).
  Article CAS Google Scholar
• Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).
  Article CAS PubMed Google Scholar
• Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G. & Lubet, R. A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 60, 5040–5044 (2000).
  CAS PubMed Google Scholar
• Levin, G., Kariv, N., Khomiak, E. & Raz, A. Indomethacin inhibits the accumulation of tumor cells in mouse lungs and subsequent growth of lung metastases. Chemotherapy 46, 429–437 (2000).
  Article CAS PubMed Google Scholar
• Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946–1952 (2000).
  Article CAS PubMed Google Scholar
• Duperron, C. & Castonguay, A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18, 1001–1006 (1997).
  Article CAS PubMed Google Scholar
• Leahy, K. M. et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62, 625–631 (2002).
  CAS PubMed Google Scholar
• Tsubouchi, Y. et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res. 20, 2867–2872 (2000).
  CAS PubMed Google Scholar
• Choy, H. & Milas, L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J. Natl Cancer Inst. 95, 1440–1452 (2003).
  Article CAS PubMed Google Scholar
• Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med. 5, 1365–1369 (1999).
  Article CAS PubMed Google Scholar
• Hussain, S. F. & Paterson, Y. CD4+CD25+ regulatory T cells that secrete TGFβ and IL-10 are preferentially induced by a vaccine vector. J. Immunother. 27, 339–346 (2004).
  Article CAS PubMed Google Scholar
• Chakraborty, N. G., Chattopadhyay, S., Mehrotra, S., Chhabra, A. & Mukherji, B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum. Immunol. 65, 794–802 (2004).
  Article CAS PubMed Google Scholar
• van Mierlo, G. J. et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J. Immunol. 173, 6753–6759 (2004).
  Article CAS PubMed Google Scholar
• Yamazaki, S. et al. Direct expansion of functional CD25+CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235–247 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Donzella, G. A. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. 4, 72–77 (1998).
  Article CAS PubMed Google Scholar
• Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001).
  Article CAS PubMed Google Scholar
• Le Bon, A. et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nature Immunol. 4, 1009–1015 (2003).
  Article CAS Google Scholar
• Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Rev. Immunol. 4, 249–258 (2004).
  Article CAS Google Scholar
• Krieg, A. M. CpG motifs: the active ingredient in bacterial extracts? Nature Med. 9, 831–835 (2003).
  Article CAS PubMed Google Scholar
• Shevach, E. M. Fatal attraction: tumors beckon regulatory T cells. Nature Med. 10, 900–901 (2004).
  Article CAS PubMed Google Scholar
• Shevach, E. M. CD4+ CD25+ suppressor T cells: more questions than answers. Nature Rev. Immunol. 2, 389–400 (2002).
  Article CAS Google Scholar
• Von Herrath, M. G. & Harrison, L. C. Regulatory lymphocytes: antigen-induced regulatory T cells in autoimmunity. Nature Rev. Immunol. 3, 223–232 (2003).
  Article CAS Google Scholar
• Sakaguchi, S. et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18–32 (2001).
  Article CAS PubMed Google Scholar
• Homann, D. et al. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 11, 463–472 (1999).
  Article CAS PubMed Google Scholar
• Bluestone, J. A. & Abbas, A. K. Opinion-regulatory lymphocytes: natural versus adaptive regulatory T cells. Nature Rev. Immunol. 3, 253–257 (2003). Discusses the concept of natural versus adaptive regulatory T cells.
  Article CAS Google Scholar
• Barrat, F. J. et al. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195, 603–616 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Groux, H. et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737–742 (1997). References 120 and 121 provide evidence that T Reg cells can be induced and that they can be functionally suppressive in vivo.
  Article CAS PubMed Google Scholar
• Woo, E. Y. et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766–4772 (2001).
  CAS PubMed Google Scholar
• Woo, E. Y. et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272–4276 (2002).
  Article CAS PubMed Google Scholar
• Liyanage, U. K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756–2761 (2002).
  Article CAS PubMed Google Scholar
• Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128–3133 (1999).
  CAS PubMed Google Scholar
• Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211–5218 (1999). References 125 and 126 were the first to report that depletion of CD25-expressing cells promotes tumour regression.
  CAS PubMed Google Scholar
• van Elsas, A. et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194, 481–489 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Steitz, J., Bruck, J., Lenz, J., Knop, J. & Tuting, T. Depletion of CD25+ CD4+ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon α-induced, CD8+ T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61, 8643–8646 (2001).
  CAS PubMed Google Scholar
• Takahashi, T. et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Read, S., Malmstrom, V. & Powrie, F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295–302 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823–832 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Turk, M. J., Guevara-Patino, J. A., Rizzuto, G. A., Engelhorn, M. E. & Houghton, A. N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771–782 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Mendez, S., Reckling, S. K., Piccirillo, C. A., Sacks, D. & Belkaid, Y. Role for CD4+ CD25+ regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J. Exp. Med. 200, 201–210 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Kuper, H., Adami, H. O. & Trichopoulos, D. Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171–183 (2000).
  Article CAS PubMed Google Scholar
• Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996). The first published study to show that CTLA4 blockade enhances tumour immunity. Human clinical trials from this group and others further prove this concept.
  Article CAS PubMed Google Scholar
• Hurwitz, A. A., Yu, T. F., Leach, D. R. & Allison, J. P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95, 10067–10071 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712–4717 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Foss, F. M. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin. Lymphoma 1, 110–106 (2000).
  Article CAS PubMed Google Scholar
• Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med. 10, 48–54 (2004).
  Article PubMed CAS Google Scholar
• Shen, L., Evel-Kabler, K., Strube, R. & Chen, S. Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nature Biotechnol. 22, 1546–1553 (2004).
  Article CAS Google Scholar
• Kwon, E. D. et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96, 15074–15079 (1999).
  Article CAS PubMed PubMed Central Google Scholar